Exelixis and Neurocrine each announce $500M share buybacks; Cosette buys Mayne for $430M; MeiraGTx seeks UK approval for blindness gene therapy; Hookipa ends Poolbeg talks.
Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate ...
As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...
Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...
Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.
Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...
Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...
Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis are seeking to block a major hospital trade group from intervening in court cases over their proposed 340B drug rebate models.
A meeting of CDC vaccine advisors has been postponed, according to a senior HHS official. “The ACIP meeting will ...
Has drug giant Roche finally cracked DNA sequencing? The company has claimed it can decode the genome in as little as four ...
The proxy filing for Accolade, a healthcare navigator that connects workers to care on behalf of their employers, agreed to ...
Keymed Biosciences is a prime example of a young Chinese biotech churning out pipeline candidates ripe for out-licensing to Western drugmakers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback